Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3240 - Hypothyroidism in cancer patients received multikinase inhibitors: Risk Factors and Outcomes

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Sitsada Hansuranant

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

S. Hansuranant1, H. Nimitphong2, O. Pattanaprateep3, R. Phraewphiphat4, D. Muntham5, T. Reungwetwattana1

Author affiliations

  • 1 Medical Oncology, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 2 Endocrinology, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 3 Section For Clinical Epidemiology And Biostatistics, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 4 Section For Data Health For Informatics Section, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 5 Department Of Mathematic, Rajamangala University of Technology Suvarnabhumi, 11000 - Nonthaburi/TH
More

Resources

Abstract 3240

Background

Hypothyroidism was a known and common side effect from multikinase inhibitors notably in sunitinib, pazopanib and sorafenib. The goal of this study was to explore risk factors in developing hypothyroid and whether the occurrence of this endocrine adverse event (AE) leading to better survival outcomes.

Methods

Seventy-one renal cell carcinoma (RCC) patients and 136 hepatocellular carcinoma (HCC) patients were retrospectively analyzed. Data relating to the treatment course and development of hypothyroid were collected, extracted and presented in separate cohort.

Results

The incidence of hypothyroidism was 47.8% in RCC patients treated with either sunitinib or pazopanib. For HCC patients whom received sorafenib, the incidence of hypothyroidism was 31.8%. We found no factor significantly associated with hypothyroidism in RCC patients. HCC patients whom had duration of treatment of less than 3 months tend to develop hypothyroidism. There was no significant association between the development of hypothyroid and PFS or OS in RCC patients. In HCC group, euthyroid patients had statistically significant longer mPFS [7.6 vs. 2.2 months; HR = 6.38; 95%CI 1.87-21.8; p = 0.003] and mOS (16.9 vs. 5.2 months; HR = 22.96; 95%CI 4.45-118; p = 0.<001) than the hypothyroid group.

Conclusions

Hypothyroid is the most common endocrine AE of multikinase inhibitors. There are no significant clinical factors associated with the development of hypothyroid. This AE might serve as a good predictive marker for multikinase inhibitors treatment in HCC patients and their survival outcomes. The larger cohort is needed to confirm this evidence.

Clinical trial identification

Legal entity responsible for the study

Faculty of Medicine Ramathibodi Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.